AN2 Therapeutics (ANTX) Operating Income (2021 - 2026)
AN2 Therapeutics (ANTX) reported Operating Income of -$10.6 million for Q1 2026, up 8.55% year-over-year from -$9.7 million in Q1 2025, and down 13.26% quarter-over-quarter from -$9.3 million in Q4 2025.
AN2 Therapeutics (ANTX) Operating Income (2021 - 2026) Analysis & Trends
AN2 Therapeutics (ANTX) has 6 years of Operating Income data on file, last reported at -$10.6 million in Q1 2026.
- Operating Income for Q1 2026 came in at -$10.6 million, up 8.55% year-over-year; the trailing twelve-month figure through Mar 2026 was -$37.1 million (up 25.8% YoY), and the FY2025 annual result was -$38.1 million, up 32.89% from the prior year.
- Operating Income eased to -$10.6 million in Q1 2026 per ANTX's latest filing, from -$9.3 million in the prior quarter.
- Over five years, Operating Income peaked at -$7.2 million in Q2 2025 and troughed at -$18.8 million in Q4 2023.
- A 5-year average of -$12.8 million and a median of -$11.8 million in 2022 frame the typical range for Operating Income.
- The sharpest annual moves came in 2022 and 2025: Operating Income plunged 274.78% in 2022, then surged 54.56% in 2025.
- A 5-year view of Operating Income shows it stood at -$12.5 million in 2022, then plunged by 50.81% to -$18.8 million in 2023, then jumped by 54.3% to -$8.6 million in 2024, then declined by 8.35% to -$9.3 million in 2025, then retreated by 13.26% to -$10.6 million in 2026.
- Business Quant data shows ANTX's Operating Income at -$10.6 million in Q1 2026, -$9.3 million in Q4 2025, and -$10.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -15.76 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -3.82 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -65.83 Mn |
| 10 | AN2 Therapeutics | 161.95 Mn | 161.95 Mn | - | -10.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.55 Mn |
| Dec 31, 2025 | -9.32 Mn |
| Sep 30, 2025 | -10.04 Mn |
| Jun 30, 2025 | -7.22 Mn |
| Mar 31, 2025 | -11.54 Mn |
| Dec 31, 2024 | -8.60 Mn |
| Sep 30, 2024 | -14.01 Mn |
| Jun 30, 2024 | -15.88 Mn |
| Mar 31, 2024 | -18.30 Mn |
| Dec 31, 2023 | -18.82 Mn |
| Sep 30, 2023 | -18.18 Mn |
| Jun 30, 2023 | -16.60 Mn |
| Mar 31, 2023 | -16.04 Mn |
| Dec 31, 2022 | -12.48 Mn |
| Sep 30, 2022 | -11.77 Mn |
| Jun 30, 2022 | -10.33 Mn |
| Mar 31, 2022 | -7.68 Mn |
| Dec 31, 2021 | -7.59 Mn |
| Sep 30, 2021 | -6.93 Mn |
| Jun 30, 2021 | -5.00 Mn |